Business context and reporting period
Filing identity differs from the request metadata: the supplied filing is for Adtalem Global Education Inc. (NYSE: ATGE), not Covista Inc. It is a Form 10-Q for the three months ended September 30, 2023, Adtalem’s first quarter of fiscal 2024—not calendar 2023 Q1. Adtalem operates Chamberlain University, Walden University, and medical and veterinary schools AUC, RUSM, and RUSVM.
Financial results and liquidity
| Metric | Quarter ended September 30, 2023 | Prior-year quarter |
|---|---|---|
| Revenue | $368.8 million | $354.3 million; +4.1% |
| Operating income / margin | $28.2 million / 7.6% | $23.6 million / 6.7% |
| Continuing-operations income | $12.0 million | $5.5 million |
| Net income | $10.6 million; diluted EPS $0.25 | $0.6 million; diluted EPS $0.01 |
| Adjusted net income / diluted EPS (non-GAAP) | $39.4 million / $0.93 | $41.6 million / $0.90 |
| Continuing-operations operating cash flow | $90.7 million | $91.5 million |
- Adjusted operating income was $63.3 million, down 5.2%; adjusted operating margin was 17.2%, versus 18.8%. GAAP operating income rose mainly as restructuring, integration, and intangible-amortization expenses declined, partly offset by an $18.5 million litigation reserve and higher bad-debt and incentive costs.
- Cost of educational services increased 5.6% to $168.6 million; as a share of revenue it rose to 45.7% from 45.1%, mainly due to higher provision for bad debts. Student services and administrative expense was $166.1 million, including higher incentive compensation, severance, growth investments, and litigation costs.
- Cash and cash equivalents were $262.4 million at September 30, versus $273.7 million at June 30; restricted cash was $2.0 million. Total assets were $2.79 billion. Current assets of $472.9 million were below current liabilities of $495.6 million.
- Cash from operating activities was $99.7 million including discontinued operations. Capital expenditures were $15.0 million. Financing used $95.4 million, including $90.5 million of cash share repurchases. The company repurchased 2.16 million shares at an average $42.57; $80.9 million remained authorized.
- Debt principal was $708.3 million ($405.0 million of 5.50% notes due 2028 and $303.3 million Term Loan B); carrying value was $695.7 million. Term Loan B interest was 9.43%. No revolver borrowings were outstanding; stated unused availability was $323.8 million before the additional Department of Education letter of credit described below. The company reported compliance with debt covenants.
Changes versus the prior comparable period
- Chamberlain revenue grew 5.3% to $142.6 million, supported by enrollment and tuition; enrollment increased 2.6% in July and 5.2% in September sessions. Adjusted operating income fell 9.9% to $24.3 million.
- Walden revenue increased 8.2% to $141.6 million; enrollment was up 0.5% year over year to 40,975. Adjusted operating income rose 26.8% to $31.1 million, while GAAP results included the litigation reserve.
- Medical and Veterinary revenue declined 3.8% to $84.6 million, with enrollment down 7.5% to 5,209, partly offset by tuition increases. Adjusted operating income fell 15.2% to $14.5 million.
- Discontinued-operations loss narrowed to $1.3 million from $4.9 million. Prior-year results included a $3.4 million disposal loss related to sale-price working-capital adjustments.
- Adtalem revised the prior-year comparison for a scholarship revenue-recognition error and other immaterial errors. It said the errors were not material to prior periods and restatement of previously filed reports was not required. The revision reduced prior-year quarterly revenue by $0.3 million and net income by $1.6 million, to $354.3 million and $0.6 million, respectively.
Outlook, risks, contingencies, and unusual items
- Management expects fiscal 2024 capital spending of $50–$60 million, including $15.0 million incurred in the quarter, for IT, Chamberlain campus development, and medical/veterinary facility improvements. It expects additional Walden integration expense during the remainder of fiscal 2024. No earnings guidance is provided in the supplied filing text.
- On September 25, 2023, the Department of Education reported Adtalem’s fiscal 2022 financial-responsibility composite score was 0.2. Its five institutions were permitted to continue Title IV participation provisionally, with heightened cash monitoring and reporting. A $157.9 million letter of credit was required by November 9, 2023; management said it did not expect the conditions to materially adversely affect operations. Issuance would reduce revolver availability to $165.9 million.
- Walden remains on a temporary provisional Title IV participation agreement, with existing letter-of-credit and cash-management conditions. The new Gainful Employment rules take effect July 1, 2024; Adtalem was reviewing their potential impact. Title IV funding eligibility and regulatory compliance are material business risks.
- In a Walden DBA class action, the parties agreed in mediation to a $28.5 million payment, subject to nonfinancial terms, Board approval, and court approval. Adtalem recorded a $28.5 million loss-contingency accrual. Separately, the segment reconciliation identifies an $18.5 million litigation reserve charge; investors should check how the current-period expense relates to the recorded liability.
- A Walden telephone-solicitation case settled for an immaterial amount, subject to court approval. Other legal and regulatory matters remain; the company says certain potential impacts cannot currently be predicted. DeVry-related indemnification obligations are subject to a $340 million contractual cap.
- Management cited potential future impairment risk if economic conditions worsen, interest rates rise, or operating results fall below expectations. It reported no goodwill or indefinite-lived intangible impairment trigger at September 30, 2023.
Most important facts for investors to verify
- Confirm the correct issuer and period: this filing is Adtalem Global Education’s FY2024 first quarter, not Covista’s 2023 Q1.
- Track delivery and terms of the $157.9 million Department of Education letter of credit, resulting revolver availability, and any changes to Title IV participation conditions.
- Verify final approval and payment terms of the proposed $28.5 million Walden settlement, and reconcile the $28.5 million accrued liability with the $18.5 million litigation-reserve charge.
- Monitor enrollment and adjusted profitability trends, particularly Medical and Veterinary declines and Walden’s recovery, alongside the increased bad-debt provision.
- Assess cash generation against share repurchases, capital spending, variable-rate debt costs, covenant thresholds, and the current-liability position.
- Consider the effects of revised prior-period figures when comparing reported results, and distinguish GAAP results from management’s non-GAAP adjusted measures.